{"created":"2021-03-01T06:19:51.172930+00:00","id":15349,"links":{},"metadata":{"_buckets":{"deposit":"0cfe511b-3aa1-4787-bfc7-567bea5f3854"},"_deposit":{"id":"15349","owners":[],"pid":{"revision_id":0,"type":"depid","value":"15349"},"status":"published"},"_oai":{"id":"oai:niigata-u.repo.nii.ac.jp:00015349","sets":["453:456","471:537:538:1085"]},"item_7_alternative_title_1":{"attribute_name":"その他のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"Pathogenic and Therapeutic Considerations on Hemodialysis-Related Amyloidosis"}]},"item_7_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2000-07","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"7","bibliographicPageEnd":"269","bibliographicPageStart":"264","bibliographicVolumeNumber":"114","bibliographic_titles":[{"bibliographic_title":"新潟医学会雑誌"},{"bibliographic_title":"新潟医学会雑誌","bibliographic_titleLang":"en"}]}]},"item_7_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Since 1985, the β2-microglobulin （β2-m） type of amyloidosis has emerged as a frequent and serious complication in patients on long-term hemodialysis. The retention of β2-m, based on impaired renal function in uremic patients, might be the main pathogenic process underlying amyloid fibril formation. Additional factors including modification of β2-m with advanced glycation end products are also suggested to contribute to the pathogenesis. However, much remains unknown regarding detailed etiology and pathogenesis of the disease. Same as for other types of amyloidosis, no radical treatment has been established. Therapeutic approaches currently taken for the amyloidosis are classified into （1）prevention of onset/progression, （2）symptomatic therapy （conservative treatment, orthopedic treatment, and physiotherapy） and （3）kidney transplantation；that is expected to be a better treatment for the amyloidosis. Because it is possible to actively remove β2-m, the precursor protein of this amyloid, the situation is greatly different from other types of amyloidosis.","subitem_description_type":"Abstract"}]},"item_7_full_name_3":{"attribute_name":"著者別名","attribute_value_mlt":[{"nameIdentifiers":[{"nameIdentifier":"98386","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Gejyo, Fumitake"}]}]},"item_7_publisher_7":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"新潟医学会"}]},"item_7_select_19":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_select_item":"publisher"}]},"item_7_source_id_11":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AN00182415","subitem_source_identifier_type":"NCID"}]},"item_7_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"00290440","subitem_source_identifier_type":"ISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"下条, 文武"}],"nameIdentifiers":[{"nameIdentifier":"98385","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-08-07"}],"displaytype":"detail","filename":"114(7)_264-269.pdf","filesize":[{"value":"968.2 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"114(7)_264-269.pdf","url":"https://niigata-u.repo.nii.ac.jp/record/15349/files/114(7)_264-269.pdf"},"version_id":"10dd7c17-feb2-435b-b0d5-85c5d8ce8f85"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"hemodialysis","subitem_subject_scheme":"Other"},{"subitem_subject":"β2-microglobulin","subitem_subject_scheme":"Other"},{"subitem_subject":"amyloidosis","subitem_subject_scheme":"Other"},{"subitem_subject":"adsorption column","subitem_subject_scheme":"Other"},{"subitem_subject":"dialysis-related amyloidosis","subitem_subject_scheme":"Other"},{"subitem_subject":"血液透析","subitem_subject_scheme":"Other"},{"subitem_subject":"β2-ミクログロブリン","subitem_subject_scheme":"Other"},{"subitem_subject":"アミロイドーシス","subitem_subject_scheme":"Other"},{"subitem_subject":"吸着カラム","subitem_subject_scheme":"Other"},{"subitem_subject":"透析アミロイドーシス","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"血液透析治療に伴うアミロイド症の病態解明と治療対策","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"血液透析治療に伴うアミロイド症の病態解明と治療対策"},{"subitem_title":"血液透析治療に伴うアミロイド症の病態解明と治療対策","subitem_title_language":"en"}]},"item_type_id":"7","owner":"1","path":["456","1085"],"pubdate":{"attribute_name":"公開日","attribute_value":"2017-11-20"},"publish_date":"2017-11-20","publish_status":"0","recid":"15349","relation_version_is_last":true,"title":["血液透析治療に伴うアミロイド症の病態解明と治療対策"],"weko_creator_id":"1","weko_shared_id":null},"updated":"2022-12-15T03:47:07.577836+00:00"}